China-focused CASI Pharmaceuticals gets Marqbio review by CFDA

China-focused and Nasdaq-listed biotech CASI Pharmaceuticals ($CASI) said Marqbio, an oncology drug, was accepted for import registration review by the China FDA. The company licensed Marqbio China rights from Spectrum Pharmaceuticals ($SPPI) in a 2014 deal covering two oncology therapies. "Marqbio is the first and only liposome-encapsulated vincristine approved and currently marketed in the U.S. for second line treatment of adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)," the company said in a release. The company said the review process is expected to include a confirmatory trial in China. In September of last year, CASI raised $25 million in a secondary offering with the funds earmarked for clinical trials. Release